← Eichor
Study identifier: NCT02732860 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host

Condition: Colorectal Neoplasms · Colorectal Cancer · Breast Cancer  ·  Sponsor: University Health Network, Toronto

PhaseN/A
Planned participants120
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

By obtaining clinical specimens from participants with triple negative breast cancer (TNBC), colorectal cancer (CRC), high grade serous ovarian cancer (HGSOC), and other select tumor types to establish and profile as freshly implanted tumors in mice, the aim of this study is to identify agents with predicted activity in the host patient while also potentially providing them with personalized cancer treatment options

This description comes directly from the study's public registry record.

Talk to the study team

David Cescon, MD  ·  416-946-2245  ·  Dave.Cescon@uhn.ca

Always discuss trial participation with your own doctor first.

Locations (1)

Princess Margaret Cancer CentreToronto, Ontario, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02732860